Clinical Results
In clinical trials, the RD-X19 treatment device has demonstrated the potential to shorten disease duration through accelerated resolution of symptoms and reduced SARS-CoV-2 virus.
3 Phases Real-World Impact
Phase #1
Human Safety
This first-in-man (FIM) study evaluated the acute safety, tolerability, and acceptability of the investigational device among healthy volunteers.
Key points
- No serious adverse events
- Device acceptable
Phase #2
Feasibility
Two studies (Early Feasibility and Dose Ranging) evaluated safety and efficacy of the RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.
Key points
- Confirmed target dose
- Identified patient population
Phase #3
Pivotal
A randomized, double-blind, sham controlled, efficacy and safety study of the RD-X19 device in individuals 40 years of age and older with Mild COVID-19 in the at-home setting.
Key points
- Sustained symptom resolution
- Time to negative test
Earn up to $1,080 in EmitBio’s Clinical Study.
Press Mentions
EmitBio to Present Research on Novel Light-Based Antiviral Therapy at the World Congress on Infectious Diseases (October 23-25, 2023)
News Article
COVID-19 treatment at home could come from Durham firm’s blue light tech
News Article
Researchers Suggest That Visible Blue Light Is a Safe and Variant-Agnostic Therapy against SARS-CoV-2
News Article
